Begin main content

insulin degludec + liraglutide

Last Updated: January 2, 2019
Result type: Reports
Project Number: SR0599-000
Product Line: Common Drug Review

Generic Name: insulin degludec + liraglutide

Brand Name: Xultophy

Manufacturer: Novo Nordisk Canada Inc.

Indications: Diabetes mellitus, Type 2

Manufacturer Requested Reimbursement Criteria1:

To be reimbursed as an adjunct to lifestyle modifications to improve glycemic control in adults with type 2 diabetes mellitus when oral glucose-lowering medications combined with basal insulin, or basal insulin alone do not provide adequate glycemic control.

Submission Type: New Combination

Project Status: Pending

Call For Patient Input: January 2, 2019

Patient Input Closed: February 21, 2019

Anticipated Date: January 30, 2019

Biosimilar: No

Fee Schedule: Pending

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Submit Feedback

Tags

diabetes